$219.88
0.06% day before yesterday
Nasdaq, Nov 28, 07:01 pm CET
ISIN
US1717571079
Symbol
CDTX

Cidara Therapeutics, Inc. Stock price

$219.88
+114.74 109.13% 1M
+197.19 869.06% 6M
+193.00 718.01% YTD
+199.68 988.51% 1Y
+205.68 1,448.45% 3Y
+173.08 369.83% 5Y
-88.52 28.70% 10Y
-100.12 31.29% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.13 0.06%
ISIN
US1717571079
Symbol
CDTX
Industry

Key metrics

Basic
Market capitalization
$6.9b
Enterprise Value
$6.5b
Net debt
positive
Cash
$420.0m
Shares outstanding
29.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
16.4
Financial Health
Equity Ratio
76.0%
Return on Equity
-104.0%
ROCE
-35.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-150.3m | $-122.9m
EBIT
$-150.5m | $-123.3m
Net Income
$-184.7m | $-180.0m
Free Cash Flow
$-132.9m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
-233.6% | -35.1%
EBIT
-232.4% | -35.2%
Net Income
-50.0% | -6.0%
Free Cash Flow
17.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-6.9
FCF per Share
$-4.5
Short interest
10.5%
Employees
38
Rev per Employee
$30.0k
Show more

Is Cidara Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Cidara Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Cidara Therapeutics, Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Cidara Therapeutics, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Cidara Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
23% 23%
-
- Research and Development Expense 132 132
186% 186%
-
-150 -150
234% 234%
-
- Depreciation and Amortization 0.16 0.16
24% 24%
-
EBIT (Operating Income) EBIT -150 -150
232% 232%
-
Net Profit -185 -185
50% 50%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cidara Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cidara Therapeutics, Inc. Stock News

Positive
Proactive Investors
2 days ago
Merck's agreement to acquire Cidara Therapeutics for about $9.2 billion gives hVIVO PLC (AIM:HVO) a moment of reflected glory. Peel Hunt's analysts highlight that Cidara's lead antiviral, CD388, advanced into late-stage development on the back of data generated through hVIVO's human challenge trial platform.
Positive
Proactive Investors
2 days ago
hVIVO PLC (AIM:HVO) has praised its long-running partner Cidara Therapeutics after the American biotech agreed to be bought by MSD in a deal worth about $9.2 billion, saying the takeover highlights the value of its specialist work in early-stage drug development. The London-listed research group, which runs human challenge trials, studies in which volunteers are deliberately exposed to a virus ...
Neutral
GlobeNewsWire
5 days ago
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) t...
More Cidara Therapeutics, Inc. News

Company Profile

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Jeffrey Stein
Employees 38
Founded 2012
Website www.cidara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today